IDYA vs MGNI
IDYA: IDEAYA Biosciences is a clinical-stage precision medicine company focused on discovering and developing targeted synthetic lethality therapies for oncology. MGNI: Magnite is a leading independent sell-side advertising platform that empowers digital publishers to maximize their revenue across CTV, video, and display formats through programmatic automation.
Side-by-side fundamentals
| Metric | IDYA | MGNI | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $31.96 | $21.49 | |
| Market cap | $3.1B | $3.1B | |
| P/E as of 2026-10-30 | n/a | 19.54 | |
| Net margin FY2025, SEC XBRL | -52.0% | +20.3% | MGNI higher |
| Operating margin FY2025, SEC XBRL | -72.8% | +13.7% | MGNI higher |
| ROE FY2025, SEC XBRL | -11.1% | +15.7% | MGNI higher |
| ROA FY2025, SEC XBRL | -10.2% | +4.6% | MGNI higher |
| Debt / equity | 0.00 | 0.37 | IDYA lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +3024.4% | +6.8% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +62.5% | +7.4% | IDYA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.97 | 1.63 | |
| 1-year return as of 2026-10-30 close | +1.1% | +24.1% | MGNI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.